PHYSICIAN AND PATIENT SURVEY OF PRACTICES AND PERSPECTIVES IN THE SURVEILLANCE AND DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) IN ASIA: UNMET NEEDS IN THE REAL WORLD

Rosmawati Mohamed^{*1}, Wendy Wang^{*2}, Tawesak Tanwandee³, Irsan Hasan⁴, Phuong Pham Cam⁵, Young-Suk Lim⁶, Sheng-Nan Lu⁷, Munisamy Murallitharan⁸, Huong Tran Thi Thanh⁹, Evy Ratnawati¹⁰, Wattana Sukeepaisarnjaroen¹¹, Mahir Karababa¹², <u>Chee-Kiat Tan</u>¹³


¹University of Malaya, Kuala Lumpur, Malaysia; ²Liver Disease Prevention and Treatment Research Foundation, Taiwan; ³Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ⁴Faculty of Medicine, University Indonesia/Ciptomangunkusumo Hospital, Indonesia; ⁵Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, and Department of Nuclear Medicine, Ha Noi Medical University, Hanoi, Vietnam; ⁶Department of Internal Medicine and Department of Gastroenterology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea; ⁷Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan; ⁸National Cancer Society of Malaysia, Jalan Raja Muda Abdul Aziz, Wilayah Persekutuan Kuala Lumpur, Malaysia; ⁹National Cancer Institute, Hanoi, and Vietnam Hanoi Medical University, Hanoi, Vietnam; ¹⁰Indonesian Cancer Information and Support Center, Indonesia; ¹¹Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; ¹²COR2ED, Basel, Switzerland; ¹³Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore;

Obesity

Smoking

*Contributed equally.

INTRODUCTION



Liver cancer is the leading cause of cancer deaths in several Asian countries. **75–85%** of cases are HCC^{1,2}

AIM

To gain insight from physicians and patients into HCC screening and diagnosis strategies used in Indonesia, Korea, Malaysia, Singapore, Taiwan, Thailand, and Vietnam

Key risk factors for HCC in Asia^{3,4}

Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection Excessive alcohol intake

Non-alcohol-related steatohepatitis (NASH)

Aflatoxin exposure Type 2 diabetes

36 questions for patients diagnosed with HCC and ≥18 years old

METHODS

Two cross-sectional, anonymised, online surveys completed between July and December 2022



55 questions for physicians who diagnose and treat HCC

RESULTS

Most physicians were hepatologists working in large hospitals and making 6–9 HCC diagnoses per month

Key physician respondents' characteristics* (n=276)	Total %
Hepatologist or gastroenterologist	66
Oncologist	17
Interventional radiologist	7
Hepatobiliary surgeon	7
Large national hospital or medical center	59
Mid-sized or regional hospital	34
Private clinic	5
1–5 HCC patients per month	22
6–9 HCC patients per month	24
10–19 HCC patients per month	26
20–49 HCC patients per month	20
50–99 HCC patients per month	6
1–5 HCC diagnoses per month	6
6–9 HCC diagnoses per month	58
10–19 HCC diagnoses per month	20
20–49 HCC diagnoses per month	12

* Only characteristics ≥5% are shown.

Most patients were male with HCC ≥2 years and diagnosed at an early stage; most were satisfied with their HCC management

Key patient respondents' characteristics* (n=130)	Total %
40–49 years	18
50–59 years	26
60–69 years	27

CONCLUSIONS

0

 Awareness should be raised in both primary care and the general population about the risk factors for HCC

- Surveillance should be improved to identify HCC at an early stage
- A lack of patient associations means that patients rely on their doctors for support; physicians need to better understand their patients' needs


 Use of trained nurses or case managers would improve patient education and support

Risk factors for HCC are widely


Change since diagnosis in

Patients understand

Primary screening method is ultrasound; biomarkers are widely used



HCC is most commonly diagnosed by multiphasic CT or MR imaging and serum AFP



References:

Zhang CH, et al. Liver Int. 2022;42:2029-41.
Sung H, et al. CA Cancer J Clin 2021;71:209-49.
Li J, et al. Lancet Gastroenterol Hepatol 2019;4:389-98.
Goh GB, et al. Best Pract Res Clin Gastroenterol 2015;29:919-28.

COR2ED THE HEART OF MEDICAL EDUCATION

Medical writing assistance was provided by COR2ED, Switzerland. Supported by an independent medical education grant from Roche.